Axiom Therapeutics
ML-driven covalent inhibitors for oncology teams.
Axiom Therapeutics has developed a covalent drug discovery platform using machine learning–accelerated physics simulations to develop more precise and potent therapies for untreatable diseases.
Founders
Ryan Geiser
CEO
Ryan is a Gates Scholar from the University of Cambridge, UK, who discovered new drugs during his PhD in Biophysical Chemistry. He then helped structure billon-dollar biopharma deals at Lazard.
Chris Haggard
CTO
Chris holds a PhD in Computational Chemistry from the University of Cambridge, UK, where he researched quantum simulation and ML methods for molecules, the core of Axiom’s technology.